Ligand Pharmaceuticals Hits New 52-Week High of $256.49

Ligand Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 256.49 on June 10, 2026. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, where it has demonstrated remarkable growth over the past year. Ligand's stock has surged by 212.13%, significantly outperforming the S&P 500, which has seen a return of 20.34% during the same period. With a market capitalization of USD 3,898 million, Ligand is classified as a small-cap company. The firm boasts a price-to-earnings (P/E) ratio of 68.00, reflecting its growth potential. Notably, Ligand has maintained a net-debt-free status, which positions it favorably in terms of financial stability. The company has reported positive results for the last three consecutive quarters, with operating cash flow reaching a high of USD 123.57 million and a net profit of USD 36.68 million, marking a growth of 157.25%. Ligand's strong fundamentals, including a return on equity of 5.61% and a price-to-book ratio of 3.83, further highlight its attractive valuation in the market.